Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Tactics used x Hedge Fund & MM to acquire shareholder stock

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 21, 2022 12:30pm

139 Views

Post# 35115748

RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

Whoever acquires ONCY will the one who makes the decision on who and where "pelareorep" will be manufactured, since those like Pfizer and Roche have both expanded their global manufacturing capacity of biological products in response to a global "in-shoring" move.

Further biological manufiacturing capacity can be effectively expanded in North America with the expansion of new marketing opportunities beyond Europe, NA and Asia.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland